Introduction
The open-label phase III Cambria-2 trial is investigating whether Camizestrant improves invasive breast cancer-free survival in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 (ER+/HER2-)-negative early breast cancer compared to standard adjuvant endocrine therapy. The target population in this study consists of patients with early-stage ER+/HER2- breast cancer at intermediate to high risk of recurrence who have completed locoregional and possibly systemic prior therapy and have not yet received standard endocrine therapy with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor.
News
Worldwide patient recruitment has begun. The first trial centre in Germany has been opened for patient recruitment in April 2024.
You are welcome to make a referral to one of our trial sites. Interested physicians can view an overview of all participating sites on the new Reesi platform.
Here you will find the link to the login area.
The inclusion and exclusion criteria as well as further information on the study design can be found in the short protocol in the list of documents.
Design
Primary study objective
Comparison of IBCFS (invasive breast cancer free survival) rates after completion of therapy
Patient profile
- ER+/HER2- breast cancer without clinical evidence of metastasis
- Intermediate to high risk of recurrence as defined in the protocol
- Pre-, peri-, and postmenopausal women and men
- Adequate surgical and systemic prior therapy with or without chemotherapy or radiotherapy
- Study inclusion before the start of adjuvant endocrine therapy, up to 12 weeks after radiotherapy or after chemotherapy
Contact
Angela Kell
